Top Page
Imugene
(Sydney:IMU)
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Imugene Business Overview & Revenue Model
Imugene Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.40M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 4.40M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -67.42M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -69.02M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 83.59M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 21.94M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 10.65M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 38.56M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 45.03M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -83.12M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -75.57M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | -12.70M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 17.37M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Imugene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$90.43M | -9.45 | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$166.28M | ― | ― | ― | ― | 0.66% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $110.36M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | $145.70M | ― | -81.03% | ― | -20.79% | 73.98% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Imugene Corporate Events
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 82% overall response rate, with seven complete and seven partial responses among the patients, many of whom had previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in aggressive blood cancer treatment. The trial is expanding to include CAR T naïve patients with various non-Hodgkin lymphomas, showing meaningful clinical activity and durability of response.
Imugene Limited announced a strategic collaboration with JW Therapeutics to advance the combination of onCARlytics (CF33-CD19) and Carteyva® for treating solid tumors. The collaboration includes a ‘mark and kill’ strategy for refractory solid tumors, potentially enhancing Imugene’s position in the immuno-oncology field. A webinar will be held to discuss this collaboration, indicating its significance for stakeholders and the company’s future operations.
Imugene Ltd and JW Therapeutics have announced a strategic collaboration to evaluate a novel combination therapy using Imugene’s onCARlytics oncolytic virus and JW’s CD19 CAR-T cell therapy, Carteyva®, targeting refractory solid tumors. This collaboration will involve preclinical studies and a Phase 1 trial in China, leveraging a ‘mark and kill’ strategy to make solid tumors targetable by CD19-CAR T cells. The initiative aims to generate impactful data efficiently and explore a breakthrough treatment paradigm for solid tumors, ensuring disciplined capital allocation and strategic flexibility.
Imugene Limited announced the results of its Annual General Meeting, highlighting a significant shareholder dissent with 30.55% voting against the Remuneration Report, marking a ‘second strike’ under the Corporations Act 2001. Despite this, the Spill Resolution was not passed, with 84.06% voting against it, indicating continued support for the current board and management.
Imugene Limited has released a disclaimer regarding its presentation for the Annual General Meeting in November 2025. The company emphasizes that the information provided does not constitute personal investment advice and should not be solely relied upon for making investment decisions. Stakeholders are advised to seek professional investment advice, as the presentation does not account for individual investment objectives or financial situations. Imugene also highlights that the presentation is not an offer to sell or solicit securities in jurisdictions where such actions would be unlawful, including the United States.
Imugene Limited announced an upcoming webinar to discuss early efficacy results from their azer-cel Phase 1b trial for CAR T naïve lymphomas and their presentation at the 67th American Society of Hematology Annual Meeting. This initiative reflects Imugene’s commitment to advancing cancer treatment and engaging stakeholders, potentially strengthening its position in the immuno-oncology market.
Imugene Limited announced that its abstract on azer-cel, an allogeneic CD19 CAR T therapy, has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting in Florida. This selection highlights the clinical interest in allogeneic CAR T approaches and provides an opportunity for Imugene to present new insights from their ongoing study on relapsed or refractory large B-cell lymphoma, potentially impacting the company’s industry positioning and stakeholder engagement.
Imugene Limited has issued 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc. as part of a milestone achievement under their License Agreement. This issuance reflects Imugene’s progress in its strategic collaboration with Precision Biosciences, potentially enhancing its market position in the immuno-oncology sector. The move signifies Imugene’s commitment to advancing its clinical and commercial milestones, aligning with its vision to become a leader in the rapidly growing global cancer treatment market.
Imugene Limited has announced the issuance of 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc., marking the achievement of a significant milestone under their License Agreement dated August 16, 2023. This development is expected to enhance Imugene’s operational capabilities and strengthen its position in the biotechnology sector by advancing its collaborative efforts with Precision Biosciences.
Imugene Limited has announced a significant milestone in its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T-cell therapy, which has achieved an 81% overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial’s success, including rapid and durable responses, positions Imugene favorably in the immuno-oncology sector, with potential implications for expanding treatment options for rare lymphomas. Additionally, the company has raised approximately $25 million through an institutional placement and share purchase plan, and received a $5.9 million R&D tax refund, bolstering its financial position to support ongoing research and development efforts.
Imugene Limited has announced promising early efficacy results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy, in CAR T-naïve patients with various B-cell lymphomas. The trial showed an 83% overall response rate and a 50% complete response rate among the six evaluable patients, with enrolment progressing faster than previous cohorts. This progress highlights the substantial clinical demand and potential for expedited clinical paths, particularly in areas of unmet need.
Imugene Limited announced that its PD1-Vaxx colorectal cancer trial will be featured at the ESMO Congress 2025, highlighting its growing international clinical presence. The Neo-POLEM Phase II trial aims to assess the efficacy of PD1-Vaxx, a novel B-cell vaccine, in treating early-stage MSI-high colorectal cancer, potentially offering an alternative to existing monoclonal antibody therapies. The trial, which began recruitment in May 2025, is a collaborative effort involving multiple sites in the UK and Australia, and seeks to improve treatment outcomes for colorectal cancer patients.
Imugene Limited has announced the quotation of 2,206 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects in cancer immunotherapy. The issuance of these securities reflects Imugene’s commitment to expanding its market presence and advancing its research and development efforts, potentially benefiting stakeholders through increased investment opportunities.
Imugene Limited has announced its 2025 Annual General Meeting, which will address key business matters such as adopting the 2025 Remuneration Report, re-electing directors, and approving equity incentives. The company has made enhancements to its remuneration approach, emphasizing transparency and alignment with performance metrics, and the board intends to forego 50% of equity incentives as a gesture of confidence in challenging capital markets.
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 81% overall response rate, with 7 complete responses and 6 partial responses among patients who have previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in the treatment of aggressive blood cancers and expands its application to other lymphoma types. The trial is actively enrolling patients in the U.S. and Australia, with additional updates expected in the coming months.